Honest discussions about treatments for dry eye disease can enhance compliance and simplify care.

Ricardo Pintor, OD, FIACLE, gives an overview of the World Council of Optometry’s first Latin America–based virtual event and what challenges Latin America faces in terms of myopia.

Catch up on what happened in optometry during the week of May 6-May 10.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Deborah Ferrington, chief scientific officer at Doheny Eye Institute, details a session she gave on May 9 regarding mitochondria and how they change with health and in the diseased retina.

Giulia Corradetti, MD, discusses study findings that changes in microperimetry are highly localized and dependent on the OCT features.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

Pucker shares topline results from a study that investigated the difference in meibomobian gland morphology when measured with a Visante OCT versus an OCULUS Keratograph 5M.

Osamah Saeedi, MD, MS, details his ARVO 2024 presentation and the study finding's implications on monitoring and treating glaucoma.

The diagnostic aid platform, C.DIAG, utilizes artificial intelligence to assist with the diagnosis and treatment of dry eye disease.

The 2 FDA registration trials for perfluorohexyloctane resulted in scientifically significant results for improvement of mild and moderate symptoms of dry eye disease.

Neda Gioia, OD, CNS, FOWNS, CFMP, details recent findings on the efficacy of the NutriTears supplement on dry eye symptoms.

Inder Paul Singh, MD, defines what it means to have an interventional mindset when it comes to glaucoma procedures and treatments during the Controversies in Modern Eye Care 2024 meeting.

Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. They concluded that children with CVI have markedly lower VS-QOL compared to typically developing children.

Marjorie Rah, OD, PhD, FAAO, discussed the in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) on patients who are considering lens dropout.

Selina McGee, OD, FAAO, shares an overview of a panel on Thyroid Eye Disease that took place at Controversies in Modern Eye Care.